HC Wainwright Cuts MacroGenics (NASDAQ:MGNX) Price Target to $2.00

MacroGenics (NASDAQ:MGNX) had its target price cut by HC Wainwright from $4.00 to $2.00 in a research note published on Tuesday, MarketBeat Ratings reports. They currently have a neutral rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for MacroGenics’ Q1 2025 earnings at ($0.69) EPS, Q2 2025 earnings at ($0.71) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.75) EPS and FY2025 earnings at ($2.89) EPS.

Separately, StockNews.com cut shares of MacroGenics from a “buy” rating to a “hold” rating in a research report on Friday, March 21st. Nine research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, MacroGenics presently has an average rating of “Hold” and a consensus target price of $7.38.

MacroGenics Price Performance

NASDAQ MGNX opened at $1.48 on Tuesday. MacroGenics has a 1 year low of $1.46 and a 1 year high of $19.54. The stock’s fifty day moving average price is $2.54 and its 200 day moving average price is $3.17. The company has a market cap of $93.37 million, a price-to-earnings ratio of -0.94 and a beta of 2.12.

MacroGenics (NASDAQ:MGNX) last issued its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). The firm had revenue of $49.40 million for the quarter, compared to analyst estimates of $34.17 million. MacroGenics had a negative return on equity of 89.42% and a negative net margin of 69.07%. Research analysts expect that MacroGenics will post -1.06 earnings per share for the current year.

Institutional Trading of MacroGenics

Several institutional investors have recently made changes to their positions in MGNX. Lazard Asset Management LLC acquired a new position in shares of MacroGenics in the 4th quarter valued at $32,000. XTX Topco Ltd acquired a new position in MacroGenics in the third quarter valued at about $37,000. American Century Companies Inc. purchased a new position in MacroGenics during the fourth quarter worth about $38,000. Sanders Morris Harris LLC acquired a new stake in shares of MacroGenics during the fourth quarter valued at about $40,000. Finally, Jump Financial LLC purchased a new stake in shares of MacroGenics in the 4th quarter valued at approximately $44,000. Hedge funds and other institutional investors own 96.89% of the company’s stock.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.